
  
    
      
        Background_NNP
        Global_JJ emergence_NN of_IN pathogenic_JJ infectious_JJ diseases_NNS by_IN
        both_DT natural_JJ and_CC intentional_JJ means_VBZ presents_VBZ a_DT formidable_JJ
        challenge_NN to_TO infectious_JJ disease_NN surveillance_NN and_CC response_NN ,_,
        namely_RB timely_JJ and_CC efficient_JJ pathogen_NN detection_NN ._. Many_JJ
        laboratory_NN methods_NNS exist_VBP for_IN identifying_VBG pathogens_NNS ,_, but_CC
        most_JJS require_VB exquisite_JJ care_NN in_IN sample_NN handling_NN and_CC
        processing_VBG prior_RB to_TO characterization_NN of_IN a_DT pathogen_NN ._. In_IN
        addition_NN ,_, costly_JJ and_CC perishable_JJ reagents_NNS ,_, equipment_NN ,_, and_CC
        supplies_NNS are_VBP required_VBN for_IN sensitive_JJ and_CC specific_JJ detection_NN ._.
        The_DT ideal_JJ detection_NN system_NN would_MD integrate_VB sample_NN
        processing_NN and_CC pathogen_NN characterization_NN into_IN a_DT single_JJ
        automated_VBN device_NN that_WDT would_MD eliminate_VB laborious_JJ ,_, and_CC time_NN
        consuming_NN sample_NN processing_NN and_CC costly_JJ detection_NN ._.
        Bioelectronic_NNP detection_NN of_IN nucleic_JJ acids_NNS on_IN a_DT miniature_JJ
        solid_JJ support_NN is_VBZ one_CD of_IN the_DT first_JJ steps_NNS toward_IN development_NN
        of_IN such_JJ an_DT integrated_VBN detection_NN device_NN ._.
        Bioelectronic_NNP DNA_NNP detection_NN involves_VBZ forming_VBG an_DT
        electronic_JJ circuit_NN mediated_JJ by_IN nucleic_JJ acid_NN hybridization_NN
        and_CC it_PRP serves_VBZ as_IN the_DT basis_NN for_IN a_DT DNA_NNP detection_NN system_NN
        called_VBD eSensor_NN ™_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. This_DT system_NN uses_VBZ low-density_NN
        DNA_NNP chips_NNS containing_VBG electrodes_NNS coated_VBN with_IN DNA_NNP capture_VB
        probes_NNS ._. Target_NNP DNA_NNP present_JJ in_IN the_DT sample_NN hybridizes_NNS
        specifically_RB both_DT to_TO capture_NN probes_NNS and_CC ferrocene_NN labeled_VBD
        signal_NN probes_NNS in_IN solution_NN thereby_RB generating_VBG an_DT electric_JJ
        current_NN ._. Current_JJ eSensor_NN DNA_NNP chips_NNS contain_VBP as_RB many_JJ as_IN 36_CD
        electrodes_NNS for_IN simultaneous_JJ detection_NN of_IN multiple_JJ pathogens_NNS
        from_IN a_DT single_JJ sample_NN ._.
        Many_JJ pathogens_NNS cause_VBP both_DT acute_JJ and_CC chronic_JJ disease_NN at_IN
        relatively_RB low_JJ copy_NN number_NN and_CC may_MD be_VB difficult_JJ or_CC
        impossible_JJ to_TO propagate_NN in_IN culture_NN ._. Thus_RB ,_, most_JJS pathogen_NN
        detection_NN systems_NNS rely_VBP on_IN nucleic_JJ acid_NN amplification_NN by_IN
        using_VBG polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) ._. One_CD highly_RB effective_JJ
        amplification_NN strategy_NN targets_VBZ conserved_JJ sequences_NNS among_IN
        the_DT family_NN of_IN organisms_NNS of_IN interest_NN ._. Such_JJ broad-range_JJ PCR_NNP
        strategies_NNS have_VBP been_VBN used_VBN to_TO identify_VB and_CC characterize_VB
        several_JJ known_VBN and_CC previously_RB uncharacterized_JJ bacteria_NNS [_NN 5_CD 6_CD
        ]_NN and_CC viruses_NNS [_NN 7_CD 8_CD ]_NN ._. In_IN order_NN to_TO maximize_VB the_DT utility_NN of_IN
        these_DT effective_JJ pathogen_NN nucleic_JJ acid_NN amplification_NN
        systems_NNS ,_, amplification_NN needs_VBZ to_TO be_VB coupled_VBN with_IN rapid_JJ ,_,
        sensitive_JJ ,_, and_CC specific_JJ detection_NN ._. Bioelectronic_NNP DNA_NNP
        detection_NN by_IN use_NN of_IN the_DT eSensor_NN chip_NN might_MD fulfill_VB this_DT
        need_VB ._.
        Human_JJ papillomaviruses_NNS (_( HPV_NNP )_) serve_VB as_IN an_DT ideal_JJ model_NN
        system_NN for_IN determining_VBG the_DT efficiency_NN and_CC feasibility_NN of_IN
        eSensor_NN DNA_NNP detection_NN technology_NN since_IN there_RB are_VBP at_IN least_JJS
        30_CD distinct_JJ genital_JJ HPV_NNP types_NNS that_WDT can_MD be_VB effectively_RB
        amplified_VBN with_IN broad-range_JJ consensus_NN PCR_NNP primers_NNS [_NN 9_CD ]_NN ._. We_PRP
        designed_VBD two_CD eSensor_NN chips_NNS ,_, each_DT containing_VBG 14_CD probes_NNS
        specific_JJ for_IN the_DT conserved_JJ L_NNP 1_CD region_NN of_IN the_DT HPV_NNP genome_NN ._. We_PRP
        evaluated_VBD clinical_JJ cervical_JJ cytology_NN samples_NNS known_VBN to_TO
        contain_VB one_CD or_CC more_JJR HPV_NNP types_NNS ._. The_DT eSensor_NN DNA_NNP detection_NN
        platform_NN successfully_RB detected_VBD the_DT correct_JJ HPV_NNP type_NN in_IN most_JJS
        of_IN these_DT clinical_JJ samples_NNS ,_, demonstrating_VBG that_IN the_DT system_NN
        provides_VBZ a_DT rapid_JJ ,_, sensitive_JJ ,_, specific_JJ ,_, and_CC economical_JJ
        approach_NN for_IN multiple-pathogen_JJ detection_NN and_CC identification_NN
        from_IN a_DT single_JJ sample_NN ._.
      
      
        Methods_NNP
        
          eSensor_NN ™_NN DNA_NNP Chip_NNP Design_NNP
          We_PRP used_VBD previously_RB described_VBD printed_VBN circuit_NN board_NN
          technology_NN to_TO manufacture_VB eSensor_NN chips_NNS with_IN 16_CD gold_JJ
          electrodes_NNS ,_, one_CD reference_NN electrode_NN ,_, and_CC one_CD auxiliary_JJ
          electrode_NN [_NN 2_CD 3_CD 4_CD ]_NN ._. Each_DT electrode_NN was_VBD wired_VBN to_TO a_DT
          connector_NN at_IN the_DT edge_NN of_IN the_DT chip_NN ._. Capture_NNP probes_NNS were_VBD
          synthesized_JJ using_VBG an_DT alkane_NN chain_NN of_IN 16_CD residues_NNS
          terminated_VBD at_IN the_DT 3_CD '_POS -_: end_NN with_IN a_DT disulfide_NN which_WDT was_VBD
          spotted_VBN onto_IN the_DT gold_NN electrode_NN on_IN the_DT chips_NNS to_TO form_VB a_DT
          self-assembled_JJ monolayer_NN [_NN 10_CD ]_NN ._. The_DT chips_NNS were_VBD glued_VBN
          into_IN a_DT plastic_NN housing_NN with_IN a_DT port_NN for_IN sample_NN
          introduction_NN ._.
          Hybsimulator_NNP (_( RNAture_NNP ,_, Inc_NNP ._. ,_, Irvine_NNP ,_, CA_NNP )_) was_VBD used_VBN to_TO
          design_VB the_DT HPV_NNP target_NN mimics_VBZ ,_, and_CC signal_NN and_CC capture_VB
          probes_NNS ._. For_IN these_DT experiments_NNS ,_, we_PRP designed_VBD capture_VB (_( Table_NNP
          1_LS )_) and_CC signal_NN (_( Table_NNP 2_LS )_) probes_NNS to_TO hybridize_NN specifically_RB
          to_TO the_DT exon_NN sequence_NN of_IN β-globin_JJ and_CC to_TO HPV_NNP sequences_NNS
          within_IN the_DT 450_CD -_: bp_NN L_NNP 1_CD region_NN amplified_VBN by_IN the_DT PGMY_NNP primer_NN
          set_VBN ._. Signal_NNP probes_NNS (_( Table_NNP 2_LS )_) tagged_VBN with_IN eight_CD ferrocenes_NNS
          were_VBD synthesized_JJ with_IN a_DT modified_VBN adenine_NN residue_NN (_( N_NNP 6_CD )_)
          containing_VBG a_DT ferrocene_NN substitution_NN on_IN the_DT ribose_NN ring_NN [_NN
          11_CD ]_NN ._. No_DT signal_NN probes_NNS were_VBD synthesized_JJ for_IN HPV_NNP types_NNS
          33_CD ,_, 39_CD ,_, 55_CD ,_, and_CC 73_CD ._. HPV_NNP target_NN mimic_VB oligonucleotides_NNS
          were_VBD synthesized_JJ for_IN types_NNS 6_CD ,_, 11_CD ,_, 16_CD ,_, 18_CD ,_, 26_CD ,_, 31_CD ,_, 35_CD ,_, 40_CD ,_,
          42_CD ,_, 45_CD ,_, 51_CD ,_, 52_CD ,_, 54_CD ,_, 56_CD ,_, 58_CD ,_, 59_CD ,_, 66_CD ,_, 68_CD ,_, 82_CD ,_, 83_CD ,_, and_CC 84_CD
          (_( Table_NNP 3_LS )_) ._.
        
        
          Sample_NNP selection_NN and_CC DNA_NNP extraction_NN
          Residual_NNP ThinPrep_NNP (_( Cytyc_NNP Corporation_NNP ,_, Boxborough_NNP ,_, MA_NNP )_)
          cervical_JJ samples_NNS previously_RB tested_VBN for_IN HPV_NNP using_VBG the_DT
          Roche_NNP line_NN blot_NN assay_NN [_NN 9_CD ]_NN were_VBD used_VBN in_IN this_DT study_NN ._.
          Twenty_CD samples_NNS containing_VBG 24_CD of_IN the_DT 27_CD HPV_NNP types_NNS on_IN the_DT
          reverse_JJ line_NN blot_NN were_VBD selected_VBN for_IN extraction_NN and_CC
          testing_NN ._. (_( No_DT samples_NNS were_VBD positive_JJ for_IN HPV_NNP 53_CD ,_, 55_CD ,_, and_CC
          57_CD ._. )_) Therefore_RB a_DT total_NN of_IN 21_CD HPV_NNP types_NNS could_MD be_VB evaluated_VBN
          (_( there_EX were_VBD 22_CD HPV_NNP capture_VB and_CC signal_VB probes_NNS minus_CC no_DT
          clinical_JJ sample_NN containing_VBG HPV_NNP 53_CD leaves_VBZ 21_CD possible_JJ HPV_NNP
          type_NN answers_NNS )_) ._. Samples_NNP were_VBD coded_VBN so_IN that_IN investigators_NNS
          were_VBD blinded_JJ to_TO the_DT presence_NN of_IN multiple_JJ HPV_NNP types_NNS ._. DNA_NNP
          was_VBD extracted_VBN from_IN 250_CD μL_NN aliquots_NNS by_IN using_VBG the_DT QIAmp_NNP DNA_NNP
          Mini_NNP Kit_NNP (_( QIAGEN_NNP Inc_NNP ._. ,_, Valencia_NNP ,_, CA_NNP )_) ._. The_DT procedure_NN
          provided_VBN with_IN the_DT kit_NN was_VBD followed_VBN except_IN that_IN the_DT
          proteinase_NN K_NNP digestion_NN was_VBD done_VBN overnight_JJ at_IN 56_CD °_NN C_NNP ._.
          Following_VBG DNA_NNP elution_NN from_IN the_DT column_NN ,_, DNA_NNP was_VBD
          concentrated_VBN in_IN a_DT Centricon_NNP Centrifugal_NNP Filter_NNP Device_NN
          YM-_NNP 100_CD (_( Millipore_NNP Corporation_NNP ,_, Bedford_NNP MA_NNP )_) according_VBG to_TO
          manufacturer_NN 's_POS specifications_NNS ._. Each_DT DNA_NNP sample_NN was_VBD
          brought_VBN to_TO 50_CD μL_NN with_IN the_DT addition_NN of_IN ultra_NN pure_JJ
          water_NN ._.
        
        
          HPV_NNP PCR_NNP and_CC Typing_NNP
          Five_CD microliters_NNS of_IN purified_JJ DNA_NNP from_IN cytology_NN samples_NNS
          was_VBD used_VBN in_IN each_DT PCR_NNP assay_NN ._. HPV_NNP DNA_NNP was_VBD amplified_VBN with_IN
          the_DT PGMY_NNP 09_CD /_NN PGMY_NNP 11_CD primer_NN system_NN that_WDT uses_VBZ a_DT multiplex_NN
          format_NN to_TO amplify_VB both_DT HPV_NNP and_CC β-globin_JJ in_IN the_DT same_JJ tube_NN
          [_NN 9_CD ]_NN ._. To_TO allow_VB for_IN strand_NN separation_NN ,_, only_RB the_DT
          downstream_JJ primers_NNS designated_VBN PGMY_NNP 11_CD and_CC one_CD β-globin_JJ
          primer_NN were_VBD biotinylated_JJ (_( Table_NNP 1_LS )_) ._. The_DT use_NN of_IN one_CD
          biotinylated_JJ primer_NN to_TO amplify_VB the_DT product_NN was_VBD still_RB
          sufficient_JJ to_TO verify_VB the_DT amplified_VBN HPV_NNP type_NN by_IN reverse_NN
          line_NN blot_NN ._. Amplification_NNP without_IN DNA_NNP template_NN was_VBD used_VBN to_TO
          monitor_VB contamination_NN ._.
          Avidin-coated_NNP beads_NNS were_VBD used_VBN to_TO harvest_NN the_DT
          biotin-labeled_JJ DNA_NNP strand_NN from_IN 50_CD μl_NN of_IN product_NN ._. The_DT
          biotin-free_JJ DNA_NNP strand_NN was_VBD then_RB used_VBN in_IN the_DT assay_NN ._.
          Briefly_NNP ,_, the_DT target_NN mimic_VB or_CC target_VB DNA_NNP was_VBD mixed_VBN with_IN a_DT
          signal_NN probe_NN cocktail_NN (_( 125_CD nM_NN of_IN each_DT signal_NN probe_NN )_) in_IN a_DT
          hybridization_NN buffer_NN (_( proprietary_JJ )_) ._. This_DT mixture_NN was_VBD
          injected_VBN into_IN the_DT eSensor_NN chip_NN for_IN hybridization_NN at_IN 40_CD °_NN C_NNP
          for_IN 2_CD to_TO 8_CD hours_NNS ._. The_DT chips_NNS were_VBD then_RB scanned_JJ by_IN an_DT AC_NNP
          voltammetry_NN technique_NN built_VBN into_IN the_DT eSensor_NN detection_NN
          device_NN called_VBD the_DT eSensor_NN 4800_CD ,_, from_IN -_: 50_CD to_TO +_NN 550_CD
          millivolts_NNS ,_, to_TO detect_VB and_CC interpret_VB the_DT electrochemical_JJ
          signal_NN generated_VBN during_IN hybridization_NN ._. Investigators_NNS
          recording_VBG eSensor_NN results_NNS remained_VBD blinded_JJ to_TO prior_RB or_CC
          current_JJ HPV_NNP results_NNS ._.
          Forty_CD microliters_NNS of_IN the_DT amplified_VBN products_NNS was_VBD also_RB
          independently_RB tested_VBN for_IN HPV_NNP using_VBG a_DT reverse_JJ line_NN probe_NN
          assay_NN (_( typing_VBG strip_NN and_CC reagents_NNS generously_RB provided_VBN by_IN
          Janet_NNP Kornegay_NNP ,_, Roche_NNP Molecular_NNP Systems_NNPS ,_, Inc_NNP ._. ,_, Alameda_NNP ,_,
          CA_NNP )_) ._. In_IN each_DT case_NN the_DT HPV_NNP results_NNS on_IN the_DT strip_NN were_VBD
          concordant_NN with_IN prior_JJ results_NNS ._. HPV_NNP detection_NN and_CC typing_VBG
          results_NNS from_IN eSensor_NN and_CC Roche_NNP were_VBD then_RB directly_RB
          compared_VBN ._.
        
      
      
        Results_NNS
        The_DT electrochemical_JJ signal_NN is_VBZ generated_VBN when_WRB the_DT HPV_NNP
        amplicon_NN hybridizes_NNS to_TO the_DT capture_NN probe_NN and_CC
        ferrocene-labeled_JJ signal_NN probe_NN ,_, thereby_RB bringing_VBG the_DT
        reporter_NN molecule_NN ,_, ferrocene_NN ,_, into_IN contact_NN with_IN the_DT
        self-assembled_JJ monolayer_NN on_IN the_DT gold_NN electrode_NN (_( Fig_NNP ._. 1_LS )_) ._. An_DT
        alternating_VBG current_JJ voltammogram_NN is_VBZ obtained_VBN when_WRB HPV_NNP is_VBZ
        detected_VBN in_IN a_DT sample_NN but_CC no_DT electronic_JJ signal_NN is_VBZ registered_VBN
        when_WRB HPV_NNP DNA_NNP is_VBZ absent_JJ from_IN the_DT sample_NN ._. (_( Fig_NNP ._. 2_LS )_) ._.
        Many_JJ of_IN the_DT HPV_NNP target_NN mimics_VBZ tested_VBN resulted_VBN in_IN a_DT
        specific_JJ signal_NN ,_, with_IN the_DT exception_NN of_IN HPV_NNP types_NNS 16_CD ,_, 26_CD ,_,
        35_CD ,_, 40_CD ,_, 42_CD ,_, 51_CD ,_, 52_CD ,_, and_CC 82_CD ._. This_DT nonspecific_JJ hybridization_NN
        signal_NN generally_RB resulted_VBD from_IN a_DT long_JJ stretch_NN of_IN
        complementary_JJ sequences_NNS (_( 6_CD -_: 8_CD bases_NNS )_) among_IN the_DT HPV_NNP types_NNS due_JJ
        to_TO their_PRP$ close_NN genetic_JJ relatedness_NNS ._. Nonspecific_NNP
        hybridization_NN was_VBD eliminated_VBN by_IN introducing_VBG a_DT mismatched_JJ
        base_NN to_TO the_DT complementary_JJ region_NN in_IN the_DT signal_NN probes_NNS for_IN
        HPV_NNP types_NNS 16_CD ,_, 26_CD ,_, 35_CD ,_, 42_CD ,_, and_CC 82_CD and_CC the_DT capture_NN probes_NNS for_IN
        HPV_NNP types_NNS 40_CD ,_, 42_CD ,_, 51_CD ,_, 52_CD ,_, and_CC 82_CD ._. For_IN instance_NN ,_, the_DT HPV_NNP 16_CD
        signal_NN probe_NN hybridized_JJ with_IN both_DT the_DT HPV_NNP 16_CD target_NN mimic_VB
        (_( Fig_NNP ._. 3_LS ,_, left_VBD panel_NN )_) and_CC the_DT HPV_NNP 52_CD capture_VB probe_NN (_( Fig_NNP ._. 3_LS ,_,
        center_NN panel_NN )_) ._. This_DT cross-reactivity_JJ was_VBD eliminated_VBN by_IN
        changing_VBG the_DT second_JJ A_DT base_NN in_IN the_DT 5_CD '_POS -_: end_NN of_IN signal_NN probe_NN to_TO
        a_DT G_NNP base_NN (_( Fig_NNP ._. 3_LS ,_, right_JJ panel_NN )_) ._. In_IN addition_NN ,_, we_PRP
        demonstrated_VBD that_IN one_CD base_NN modification_NN of_IN the_DT signal_NN probe_NN
        (_( Fig_NNP ._. 3_LS ,_, left_VBD and_CC right_JJ panels_NNS )_) generated_VBN minimal_JJ negative_JJ
        impact_NN to_TO the_DT assay_NN signal_NN level_NN ._. Applying_VBG this_DT strategy_NN ,_,
        we_PRP were_VBD able_JJ to_TO effectively_RB reduce_VB the_DT cross-reactivity_JJ
        among_IN the_DT signal_NN and_CC capture_VB probes_NNS for_IN those_DT HPV_NNP types_NNS
        where_WRB problems_NNS of_IN non-specific_JJ signal_NN had_VBD initially_RB been_VBN
        encountered_VBN without_IN compromising_VBG hybridization_NN
        strengths_NNS ._.
        In_IN most_JJS instances_NNS for_IN the_DT 20_CD samples_NNS tested_VBN ,_, there_EX was_VBD
        perfect_JJ concordance_NN between_IN the_DT HPV_NNP type_NN (_( s_VBZ )_) detected_VBN by_IN
        reverse_NN line_NN blot_NN and_CC the_DT eSensor_NN system_NN (_( Table_NNP 4_LS )_) ._. The_DT
        eSensor_NN detected_VBD 18_CD (_( 86_CD %_NN )_) of_IN 21_CD HPV_NNP types_NNS ._. In_IN samples_NNS with_IN
        multiple_JJ HPV_NNP types_NNS amplified_VBN by_IN the_DT consensus_NN primer_NN system_NN
        and_CC typed_VBN by_IN reverse_NN line_NN blot_NN (_( but_CC blinded_JJ to_TO the_DT
        individual_JJ conducting_NN the_DT eSensor_NN assay_NN )_) ,_, the_DT eSensor_NN
        successfully_RB detected_VBD the_DT multiple_JJ HPV_NNP targets_NNS in_IN all_DT six_CD
        samples_NNS (_( Table_NNP 4_LS )_) ._.
      
      
        Discussion_NNP
        We_PRP have_VBP presented_VBN a_DT model_NN application_NN of_IN a_DT novel_NN
        electronic_JJ detection_NN platform_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. We_PRP used_VBD HPV_NNP as_IN
        a_DT model_NN infectious_JJ disease_NN system_NN because_IN consensus_NN primers_NNS
        are_VBP available_JJ that_WDT amplify_VB at_IN least_JJS 30_CD closely_RB related_VBN
        genital_JJ HPV_NNP types_NNS ._. The_DT resulting_VBG amplicons_NNS are_VBP extremely_RB
        similar_JJ ,_, and_CC this_DT relatedness_NNS challenges_VBZ the_DT ability_NN of_IN the_DT
        eSensor_NN technology_NN to_TO distinguish_VB accurately_RB among_IN these_DT
        pathogens_NNS ._. The_DT first_JJ optimization_NN steps_NNS involved_VBD evaluation_NN
        of_IN electrochemical_JJ signal_NN generation_NN by_IN using_VBG HPV_NNP target_NN
        mimics_NNS ._. Cross-hybridization_NNP was_VBD observed_VBN between_IN a_DT subset_NN
        of_IN HPV_NNP target_NN mimics_VBZ and_CC the_DT capture_NN and_CC signal_VB probes_NNS ._.
        This_DT cross-hybridization_JJ was_VBD easily_RB overcome_VBN by_IN the_DT
        introduction_NN of_IN mismatched_JJ base_NN pairs_NNS ._. The_DT effectiveness_NN of_IN
        single-base_JJ mismatch_NN discrimination_NN of_IN the_DT eSensor_NN has_VBZ been_VBN
        demonstrated_VBN by_IN using_VBG wild_JJ type_NN and_CC mutant_JJ strains_NNS of_IN human_JJ
        immunodeficiency_NN virus_NN [_NN 3_CD ]_NN ._.
        We_PRP used_VBD the_DT eSensor_NN DNA_NNP chip_NN to_TO determine_VB the_DT presence_NN
        of_IN single_JJ or_CC multiple_JJ HPV_NNP types_NNS in_IN cervical_JJ cytology_NN
        samples_NNS ._. While_IN the_DT presence_NN of_IN the_DT target_NN HPV_NNP type_NN was_VBD
        known_VBN ,_, the_DT presence_NN of_IN other_JJ HPV_NNP types_NNS in_IN the_DT same_JJ sample_NN
        remained_VBD blinded_JJ (_( e_SYM ._. g_SYM ._. ,_, the_DT HPV_NNP 42_CD in_IN a_DT clinical_JJ sample_NN was_VBD
        identified_VBN but_CC the_DT presence_NN of_IN HPV_NNP 68_CD in_IN the_DT same_JJ sample_NN
        was_VBD not_RB known_VBN to_TO those_DT performing_VBG electrochemical_JJ
        detection_NN )_) ._. There_EX was_VBD good_JJ concordance_NN for_IN the_DT detection_NN of_IN
        the_DT target_NN HPV_NNP type_NN by_IN the_DT eSensor_NN DNA_NNP Detection_NNP System_NNP ._.
        Eighteen_CD (_( 86_CD %_NN )_) of_IN 21_CD target_NN HPV_NNP types_NNS represented_VBD on_IN the_DT
        chip_NN were_VBD readily_RB detected_VBN by_IN the_DT eSensor_NN (_( Table_NNP 4_LS )_) ;_: HPV_NNP
        40_CD ,_, 45_CD and_CC 54_CD were_VBD not_RB detected_VBN ._. Some_DT of_IN the_DT other_JJ
        discrepancies_NNS could_MD be_VB due_JJ to_TO lack_NN of_IN rigorous_JJ optimization_NN
        of_IN sensitivity_NN parameters_NNS for_IN the_DT eSensor_NN system_NN ,_, such_JJ as_IN
        the_DT weak_JJ HPV_NNP 54_CD result_NN on_IN reverse_NN line_NN blot_NN and_CC lack_NN of_IN
        detection_NN on_IN eSensor_NN ._. Low-level_NNP signals_NNS on_IN the_DT line_NN probe_NN
        assay_NN have_VBP been_VBN validated_JJ by_IN sequencing_VBG the_DT amplified_VBN
        product_NN [_NN 12_CD ]_NN ._. For_IN HPV_NNP 40_CD discrepancy_NN ,_, the_DT capture_NN probe_NN
        design_NN may_MD not_RB have_VB been_VBN optimal_NN to_TO allow_VB for_IN hybridization_NN
        with_IN the_DT HPV_NNP 40_CD target_NN ._. These_DT HPV_NNP types_NNS may_MD be_VB variant_NN
        types_NNS that_WDT did_VBD not_RB hybridize_NN to_TO the_DT capture_NN probe_NN and_CC
        subsequently_RB could_MD not_RB be_VB detected_VBN by_IN the_DT signal_NN probe_NN ._. Not_RB
        only_RB are_VBP there_RB over_IN 200_CD HPV_NNP types_NNS ,_, but_CC several_JJ sequence_NN
        variants_NNS of_IN HPV_NNP types_NNS are_VBP known_VBN to_TO exist_VB [_NN 13_CD ]_NN ._. Most_JJS
        hybridization_NN reactions_NNS could_MD be_VB analyzed_VBN after_IN 2_CD hours_NNS ,_,
        although_IN in_IN several_JJ instances_NNS up_IN to_TO 8_CD hours_NNS of_IN
        hybridization_NN time_NN was_VBD required_VBN ._. The_DT intent_NN of_IN this_DT study_NN
        was_VBD to_TO use_VB HPV_NNP as_IN a_DT model_NN system_NN to_TO assess_VB the_DT feasibility_NN
        of_IN electrochemical_JJ detection_NN with_IN the_DT eSensor_NN chip_NN of_IN
        multiple_JJ pathogens_NNS ,_, not_RB to_TO achieve_VB perfect_JJ concordance_NN of_IN
        HPV_NNP detection_NN with_IN the_DT reverse_JJ line_NN blot_NN ._.
        In_IN this_DT model_NN assay_NN ,_, we_PRP have_VBP performed_VBN optimization_NN of_IN
        probe_NN sequences_NNS and_CC assay_NN protocol_NN by_IN using_VBG synthesized_JJ
        target_NN mimics_NNS ._. The_DT resultant_JJ assay_NN correctly_RB identified_VBD
        nearly_RB all_DT HPV_NNP type_NN in_IN the_DT clinical_JJ samples_NNS ._. No_DT attempt_NN to_TO
        further_VB optimize_NN the_DT assay_NN using_VBG PCR_NNP amplicons_NNS ,_, rather_RB than_IN
        target_NN mimics_VBZ ,_, was_VBD made_VBN and_CC neither_DT was_VBD the_DT PCR_NNP process_NN
        optimized_JJ for_IN detection_NN by_IN using_VBG the_DT eSensor_NN DNA_NNP detection_NN
        system_NN ._. This_DT work_NN demonstrates_VBZ the_DT ease_NN with_IN which_WDT a_DT
        multi-analyte_JJ panel_NN assay_NN can_MD be_VB prototyped_JJ using_VBG the_DT
        eSensor_NN DNA_NNP detection_NN system_NN ._. For_IN clinical_JJ applications_NNS ,_,
        the_DT prototype_NN assay_NN can_MD be_VB readily_RB fine-tuned_JJ by_IN optimizing_VBG
        the_DT conditions_NNS for_IN PCR_NNP and_CC hybridization_NN to_TO yield_VB
        concordance_NN levels_NNS approaching_VBG 100_CD %_NN (_( data_NNS not_RB
        published_VBN )_) ._.
      
      
        Conclusions_NNP
        The_DT bioelectronic_JJ detection_NN platform_NN described_VBD here_RB
        includes_VBZ disposable_JJ DNA_NNP chips_NNS and_CC laboratory-based_JJ
        electronic_JJ readers_NNS and_CC is_VBZ a_DT first-generation_JJ system_NN that_IN
        ultimately_RB will_MD facilitate_VB the_DT development_NN of_IN relatively_RB
        low_JJ cost_NN ,_, arrayed_JJ nucleic_JJ acid-based_JJ tests_NNS ._. For_IN widespread_JJ
        clinical_JJ laboratory_NN adoption_NN ,_, these_DT arrays_NNS must_MD have_VB
        clinically_RB appropriate_JJ densities_NNS compatible_JJ with_IN the_DT needs_NNS
        of_IN molecular_JJ diagnostics_NNS laboratories_NNS ,_, (_( 
        i_NNP ._. e_SYM ._. ,_, low_JJ cost_NN and_CC not_RB
        labor-intensive_JJ )_) ._. The_DT system_NN described_VBD could_MD also_RB be_VB
        developed_VBN as_IN a_DT foundation_NN for_IN devices_NNS to_TO be_VB used_VBN for_IN
        point-of-care_JJ testing_NN for_IN other_JJ infectious_JJ diseases_NNS ._.
      
      
        Competing_VBG Interests_NNP
        Authors_NNP SDV_NNP ,_, ERU_NNP ,_, DLM_NNP ,_, and_CC WCR_NNP declare_VBP no_DT competing_VBG
        interests_NNS ._. Authors_NNP DHF_NNP ,_, VC_NNP ,_, YPC_NNP and_CC GFB_NNP are_VBP employees_NNS or_CC
        are_VBP currently_RB employed_VBN at_IN Motorola_NNP Life_NNP Sciences_NNPS whose_WP$
        technology_NN this_DT work_NN was_VBD based_VBN ._. Both_DT DHF_NNP and_CC GFB_NNP own_JJ or_CC
        previously_RB held_VBN Motorola_NNP Stock_NNP ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        Author_NN 1_CD (_( SDV_NNP )_) contributed_VBD to_TO the_DT conception_NN and_CC design_NN
        of_IN this_DT study_NN ,_, the_DT analysis_NN of_IN the_DT results_NNS and_CC drafted_VBD the_DT
        manuscript_NN ._. Author_NN 2_CD (_( DHF_NNP )_) contributed_VBD to_TO the_DT design_NN of_IN the_DT
        experimental_JJ approach_NN using_VBG the_DT bioelectric_JJ chip_NN ,_,
        implemented_VBD the_DT experimental_JJ approach_NN ,_, and_CC assisted_VBN in_IN
        drafting_VBG the_DT manuscript_NN ._. Author_NN 3_CD (_( ERU_NNP )_) contributed_VBD to_TO the_DT
        conception_NN and_CC design_NN of_IN this_DT study_NN ,_, the_DT analysis_NN of_IN the_DT
        results_NNS and_CC drafted_VBD the_DT manuscript_NN ._. Author_NN 4_CD (_( VC_NNP )_) conducted_VBD
        the_DT laboratory_NN work_NN at_IN Clinical_NNP Microsensors_NNP ._. Author_NN 5_CD
        (_( DLM_NNP )_) conducted_VBD all_DT laboratory_NN work_NN involving_VBG sample_NN
        preparation_NN ,_, amplification_NN and_CC typing_VBG of_IN human_JJ
        papillomaviruses_NNS at_IN CDC_NNP ._. Author_NN 6_CD (_( YPC_NNP )_) conducted_VBD the_DT
        laboratory_NN work_NN at_IN Clinical_NNP Microsensors_NNP ._. Author_NN 7_CD (_( GFB_NNP )_)
        supported_VBD the_DT memorandum_NN of_IN understanding_NN between_IN Clinical_NNP
        Microsensors_NNP and_CC CDC_NNP and_CC edited_JJ the_DT manuscript_NN ._. Author_NN 8_CD
        (_( WCR_NNP )_) contributed_VBD to_TO the_DT conception_NN and_CC design_NN of_IN this_DT
        study_NN ,_, assisted_VBN in_IN drafting_VBG the_DT manuscript_NN and_CC supported_VBD
        the_DT memorandum_NN of_IN understanding_NN between_IN Clinical_NNP
        Microsensors_NNP and_CC CDC_NNP ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
